Company Encyclopedia
View More
name
CureVac BV
CVAC.US
As of December 18, 2025, CureVac N.V. was acquired by BioNTech SE. CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company’s portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy.
1.912 T
CVAC.USMarket value -Rank by Market Cap -/-

Financial Score

20/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking215/400
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE0.00%D
    • Profit Margin182.11%A
    • Gross Margin99.31%A
  • Growth ScoreD
    • Revenue YoY-86.69%E
    • Net Profit YoY21.61%B
    • Total Assets YoY0.00%C
    • Net Assets YoY0.00%C
  • Cash ScoreD
    • Cash Flow Margin54.91%C
    • OCF YoY-86.69%E
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreB
    • Gearing Ratio23.48%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    BioNTech Wraps Up Exchange Offer to Buy CureVac

    BioNTech Wraps Up Exchange Offer to Buy CureVac

    marketscreener·
    US
    BNTX
    +1.14%
    US
    CVAC
    -2.80%
    marketscreener·
    US
    BNTX
    +1.14%
    US
    CVAC
    -2.80%

    BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field | BNTX Stock News

    BioNTech has completed its acquisition of CureVac, enhancing its mRNA capabilities. Approximately 86.75% of CureVac shares were tendered, with the remaining shares expected to be acquired by January 2026. CureVac will continue its operations while BioNTech integrates strategic and scientific analyses. This acquisition strengthens BioNTech's position in the mRNA field and supports its oncology strategy. The management board of CureVac will be reconstituted following the acquisition.

    StockTitan·
    US
    BNTX
    +1.14%
    US
    CVAC
    -2.80%
    StockTitan·
    US
    BNTX
    +1.14%
    US
    CVAC
    -2.80%

    BioNTech Secures 81.7% of CureVac Shares in Tender Offer

    BioNTech has initiated an offer to exchange American Depositary Shares for CureVac shares, securing 81.7% of CureVac shares. Relevant documents have been filed with the U.S. SEC, and CureVac has submitted a recommendation statement. This information is based on a news brief created by Public Technologies using AI and originally published by BioNTech via GlobeNewswire on December 03, 2025.

    Reuters·
    US
    CVAC
    -2.80%
    US
    BNTX
    +1.14%
    Reuters·
    US
    CVAC
    -2.80%
    US
    BNTX
    +1.14%

    Can New Board Leadership at CureVac (CVAC) Shift the Narrative After Recent Earnings Decline?

    CureVac N.V. held an Extraordinary General Meeting, appointing Ramón Zapata Gomez as managing director and new supervisory directors amid declining earnings. The board changes aim to stabilize leadership but don't alter near-term clinical program catalysts or revenue risks. A settlement with GSK provides financial support, yet milestone payment uncertainties remain. CureVac projects €157.1 million in revenue and €16.6 million in earnings by 2028, with a fair value estimate showing a 3% downside. Investors are advised to consider potential disruptions and explore alternative investment strategies.

    Simplywall·
    US
    CVAC
    -2.80%
    Simplywall·
    US
    CVAC
    -2.80%

    BioNTech Public Exchange Offer for CureVac Secures Shareholder Approval

    BioNTech announced that CureVac shareholders approved the exchange offer with 99.16% voting in favor. The exchange ratio is set at 0.05363 BioNTech ADS for each CureVac share. BioNTech expects to complete the offer soon.

    fidelity·
    US
    BNTX
    +1.14%
    fidelity·
    US
    BNTX
    +1.14%
    Posts
    View More
    © 2025 Longbridge｜Disclaimer